PT DOAC is used for functional determination of the extrinsic pathway of the coagulation cascade in patients treated with direct oral anticoagulants (DOACs).
A simple and rapid assay for functional determination of DOAC effect has been needed since the introduction of DOACs. A major drawback of using conventional coagulation tests for estimation of DOAC effect is the substantial variability in the sensitivity to DOACs amongst different reagents. Nordic Biomarker has taken this disadvantage into account in the development of PT DOAC. This novel prothrombin time (PT) method utilizes a concept already proven for warfarins. As a conventional PT determines the effect of warfarin and not the concentration, PT DOAC determines the effect of DOACs and not the concentration. Furthermore, only one reagent is needed to detect the effect of all the DOACs. The method is patented in Europe (EP31416347) and a world-wide patent (WO2015177293) is pending.
We are currently looking for collaborators that are interested in working with us to evaluate the clinical usefulness of this For Research Use Only Product.